Background Despite extensive vaccine efforts, central nervous system (CNS) infections remain a significant cause of morbidity and mortality in the African meningitis belt. This is increasingly complicated by the rising antimicrobial resistance (AMR) in pathogens not covered by the vaccine. We mapped pathogen-specific AMR profiles and diagnostic gaps in CNS bacterial pathogens to inform precision microbiological-based interventions for improved surveillance and empiric therapy in Nigeria.

Methods We conducted a retrospective analysis of a three year national AMR surveillance data, focusing on CNS bacterial pathogens. Data from 25 sentinel laboratories were extracted, analysed and interpreted per CLSI/GLASS standards. AMR profiles and diagnostic gaps were assessed using descriptive statistics and Chi-square tests for demographic and temporal comparisons.

Results Among all 84,548 valid cultures from over 26,000 patients, culture positivity rate was higher in females (35.1%) and older adults (>65 years, 40.0%, p < 0.001). CSF specimens were underrepresented, while species-level ambiguity was high for CNS-associated infections. Staphylococcus aureus, Escherichia coli and Klebsiella species were the dominant isolates, while Pseudomonas aeruginosa and Acinetobacter species showed persistent low-level presence. Alarmingly, Streptococcus pneumoniae showed rising penicillin resistance, reaching 100% by 2018. Other pathogens, including Klebsiella species, E. coli, and Pseudomonas aeruginosa showed high AMR across multiple drug classes. Gap analysis scored all CNS associated bacterial pathogens at maximum clinical risk (5/5), with major deficits in detection and the laboratory capacity. A precision-targeted recommendation map tailored microbiological interventions, such as neonatal AST protocol for E. coli and ICU infection registries for Pseudomonas species.

Conclusion Species-level identification gaps and high AMR in CNS infections bacterial pathogens demand targeted microbiological-led diagnostics to include expanded CSF testing and AST-guided empiric therapy in resource-limited settings.

Highlights

First national AMR gap analysis for CNS pathogens across 84,000 cultures in Nigeria

Links resistance trends with diagnostic gaps for tailored stewardship interventions

Introduces scalable microbiology-driven precision surveillance for LMIC settings

Informs treatment protocols, lab policies and strategies for high-risk CNS infections

The authors have declared no competing interest.

This study did not receive any funding

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study utilized publicly available, de-identified AMR surveillance data originally collected by the Nigerian Ministry of Health under the Fleming Fund Regional Grant (Phase 1) https://aslm.org/wp-content/uploads/2023/07/AMR_REPORT_NIGERIA.pdf?x89467

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes

This study utilized publicly available, de-identified AMR surveillance data originally collected by the Nigerian Ministry of Health under the Fleming Fund Regional Grant (Phase 1) No individual-level data were accessed. Secondary data use complied with the Declaration of Helsinki and did not require additional ethical clearance.

https://aslm.org/wp-content/uploads/2023/07/AMR_REPORT_NIGERIA.pdf?x89467.